<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Aurinia Pharmaceuticals Inc. AUPHAUP, a clinical stage 
 biopharmaceutical company focused on the global immunology market, today 
 announced that is has been selected to present late breaking oral 
 presentations at both the 54th European Renal 
 Association-European Dialysis and Transplant Association's (ERA-EDTA) 
 Congress and the Annual European Congress of Rheumatology (EULAR) 2017, 
 on June 3th-6th, 2017, Madrid, Spain and June 14-17, Madrid, 
 Spain, respectively.
 
 
 "The selection of the 48-week data from our successful AURA-LV Phase 2 
 study for two late-breaking oral presentations during these key medical 
 meetings underscores the high impact of the results to the broader 
 physician community, said Neil Solomons, M.D., Aurinia's Chief Medical 
 Officer. "We look forward to sharing our findings and highlighting the 
 importance of developing a potential therapy for active lupus nephritis."
 
 
 Below is the schedule for the oral presentations:
 
 
 54th European Renal Association-European 
 Dialysis and Transplant Association's (ERA-EDTA) Congress Date: 
 Sunday, June 4, 2017 Time: 11:45 a.m. GMT Location: 
 FEMA Feria de Madrid (North Congress Center) Title: 
 Steroid-Sparing Efficacy of Voclosporin in Active Lupus Nephritis: 
 Stable Kidney Function and BP Without Electrolyte Complications at 48 
 Weeks
 
 
 Annual European Congress of Rheumatology (EULAR) 2017 Date: 
 Friday, June 16, 2017 Poster Presentation Time: 11:20 a.m. 
 GMT Location: Hall 7B Title: 48 Week Complete 
 Remission of Active Lupus Nephritis With Voclosporin
 
 
 Editor's Note: James Tumlin, M.D., study investigator for 
 Aurinia, will be participating in a press briefing at the 54th 
 ERA-EDTA Congress on Sunday, June 4, 2017 at 9:30 a.m. to present the 
 study, "Steroid-Sparing Efficacy of Voclosporin in Active Lupus 
 Nephritis: Stable Kidney Function and BP Without Electrolyte 
 Complications at 48 Weeks". He will be presenting the study in FEMA 
 Feria de Madrid (North Congress Center), Room N112.
 
 
 About Aurinia Aurinia is a clinical stage 
 biopharmaceutical company focused on developing and commercializing 
 therapies to treat targeted patient populations that are suffering from 
 serious diseases with a high unmet medical need. The Company is 
 currently developing voclosporin, an investigational drug, for the 
 treatment of lupus nephritis (LN), in an inflammation of the kidney 
 caused by Systemic Lupus Erythematosus (SLE) and represents a serious 
 progression of SLE. The Company is headquartered in Victoria, BC and 
 focuses its development efforts globally.
 
 
 Visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.auriniapharma.com&amp;esheet=51567001&amp;newsitemid=20170530006319&amp;lan=en-US&amp;anchor=www.auriniapharma.com&amp;index=1&amp;md5=9b5dbf7c811e674ef0b73e4b74d16640" rel="nofollow" rel="nofollow">www.auriniapharma.com</a> for 
 more information.
 
 
 Forward Looking Statements This press release 
 contains forward-looking statements, including statements related to 
 Aurinia&#39;s analysis, assessment, conclusions and impact of the results of 
 the AURA-LV clinical study, and the efficacy and safety of voclosporin. 
 It is possible that such results or conclusions may change based on 
 further analyses of these data. Words such as &#34;plans,&#34; &#34;intends,&#34; "may," 
 &#34;will,&#34; &#34;believe,&#34; and similar expressions are intended to identify 
 forward-looking statements. These forward-looking statements are based 
 upon Aurinia's current expectations. Forward-looking statements involve 
 risks and uncertainties. Aurinia's actual results and the timing of 
 events could differ materially from those anticipated in such 
 forward-looking statements as a result of these risks and uncertainties, 
 which include, without limitation, the risk that Aurinia's analyses, 
 assessment and conclusions of the results of the AURA-LV clinical study 
 set forth in this release may change based on further analyses of such 
 data, and the risk that Aurinia's clinical studies for voclosporin may 
 not lead to regulatory approval. These and other risk factors are 
 discussed under &#34;Risk Factors&#34; and elsewhere in Aurinia's Annual 
 Information Form for the year ended December 31, 2016 filed with 
 Canadian securities authorities and available at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=51567001&amp;newsitemid=20170530006319&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=2&amp;md5=2f191a7f1710366cab4bc36e2bb60f53" rel="nofollow" rel="nofollow">www.sedar.com</a> 
 and on Form 40-F with the U.S. Securities Exchange Commission and 
 available at <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51567001&amp;newsitemid=20170530006319&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=99fc5d498383014274b8d0c84fd6ad7a" rel="nofollow" rel="nofollow">www.sec.gov</a>, 
 each as updated by subsequent filings, including filings on Form 6-K. 
 Aurinia expressly disclaims any obligation or undertaking to release 
 publicly any updates or revisions to any forward-looking statements 
 contained herein to reflect any change in Aurinia&#39;s expectations with 
 regard thereto or any change in events, conditions or circumstances on 
 which any such statements are based.
 
 
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170530006319r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170530006319/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170530006319/en/</a></body></html>

Press Releases

Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences - Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals

AUPH

TSX:AUP

Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences

BMV:ORBIA


Orbia Advance Corporation, S.A.B. de C.V. (BMV:ORBIA) (&#34;the Company&#34; or &#34;Orbia&#34;) today released unaudited results for the first quarter of 2024.


Orbia&#39;s first quarter performance reflects the continued weakness in the

Orbia Announces First Quarter 2024 Financial Results


AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an

AHF Praises Colombia for Putting Lives Before Pharma Greed


Freeport-McMoRan Inc. (NYSE:FCX) today announced the publication of its 2023 Annual Report on Sustainability detailing its environmental, social and governance performance during the year. This report marks FCX&#39;s 23rd

Freeport-McMoRan Publishes 2023 Annual Report on Sustainability



Delivers $0.36 of diluted earnings per share (EPS), a slight year-over-year decrease of $0.01



Invests $69 million in infrastructure



Secures 10.01% Water Cost of Capital Mechanism (WCCM)-adjusted return on equity

SJW Group Announces First Quarter 2024 Financial Results

TBBB


BBB Foods Inc. (&#34;Tiendas 3B&#34; or the &#34;Company&#34;) (NYSE:TBBB), a leading grocery hard discounter in Mexico, announced today its consolidated results for the fourth quarter of 2023 (4Q23) and full fiscal year 2023 ended

Tiendas 3B 4Q23 &amp; FY2023 Earnings Release


MoneyLion Inc. (&#34;MoneyLion&#34;) (NYSE:ML), a leader in financial technology powering the next generation of personalized products and content, today announced its participation at the following investor conferences in